Malignant Peripheral Nerve Sheath Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MPNST MCID: MLG077 MIFTS: 56	Malignant Peripheral Nerve Sheath Tumor (MPNST) malady Categories: Rare diseases, Neuronal diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

Sources:
¹¹Disease Ontology, ¹³DISEASES, ³¹ICD10 via Orphanet, ³⁹MeSH, ⁴⁵NCIt, ⁴⁸NIH Rare Diseases, ⁵⁰Novoseek, ⁵⁴Orphanet, ⁶²SNOMED-CT, ⁶⁸UMLS, ⁶⁹UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor ¹¹ ⁴⁸ ⁵⁴ ¹³ ⁶⁸

Malignant Neurilemmoma ⁴⁸ ⁵⁴ ⁵⁰

Neurofibrosarcoma ⁴⁸ ⁵⁴ ⁶⁸

Mpnst ⁴⁸ ⁵⁴ ⁵⁰

Malignant Neurofibroma ⁴⁸ ⁵⁴

Malignant Schwannoma ⁴⁸ ⁵⁴

Neurogenic Sarcoma ⁴⁸ ⁵⁴

Malignant Neoplasm of the Peripheral Nerve Sheath ¹¹

Malignant Peripheral Nerve Sheath Tumors ⁵⁰

Characteristics:

Orphanet epidemiological data:

⁵⁴

malignant peripheral nerve sheath tumor:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly,Infancy; Age of death: adolescent,adult,early childhood,elderly,infantile,late childhood,young Adult

Classifications:

MalaCards categories:
Global: Rare diseases, Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Malignant neoplasm of peripheral nerves and autonomic nervous system

Malignant neoplasm: Peripheral nerves and autonomic nervous system, unspecified

Orphanet: ⁵⁴

Rare neurological diseases

External Ids:

Disease Ontology¹¹ DOID:5940

MeSH³⁹ D009442

NCIt⁴⁵ C3798

SNOMED-CT⁶² 134324009, 189949003, 19897006 404037002, 77418004, more

Orphanet⁵⁴ ORPHA3148

UMLS via Orphanet⁶⁹ C0751690

ICD10 via Orphanet³¹ C47.9

UMLS⁶⁸ C0751690

Summaries for Malignant Peripheral Nerve Sheath Tumor

Sources:
³⁶MalaCards, ⁴⁸NIH Rare Diseases, ⁷¹Wikipedia
See all MalaCards sources

NIH Rare Diseases:⁴⁸ A malignant peripheral nerve sheath tumor (mpnst) is a tumor that develops in the protective lining that covers nerves. the first symptom of mpnst is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. mpnst is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. treatment of mpnst begins with surgery to remove as much of the tumor as possible. radiation therapy may be used to decrease the chance of a recurrence. chemotherapy might be used if the whole tumor cannot be removed during surgery, or to treat a metastasis. mpnsts are quite rare, occurring in 0.001% of the general population. approximately 25-50% of mpnsts are associated with a genetic condition known as neurofibromatosis type 1. last updated: 8/18/2016

MalaCards based summary: Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to seminoma and gastrointestinal stromal tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is HTRA1 (HtrA Serine Peptidase 1), and among its related pathways are Gefitinib Pathway, Pharmacokinetics and ATF-2 transcription factor network. Affiliated tissues include lung, breast and kidney, and related mouse phenotypes are Increased proliferation and Decreased cell migration.

Wikipedia:⁷¹ A malignant peripheral nerve sheath tumor (MPNST) (also known as \"malignant schwannoma\",... more...

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

Sources:
²⁰GeneAnalytics, ²¹GeneCards
See all MalaCards sources

Diseases in the Benign Peripheral Nerve Sheath Tumor family:

malignant peripheral nerve sheath tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)

id	Related Disease	Score	Top Affiliating Genes
1	seminoma	29.9	CHGA, NF2, TP53
2	gastrointestinal stromal tumor	28.7	ACTC1, CDKN2A, CHGA, EGFR, KIT, NF1
3	epithelioid malignant peripheral nerve sheath tumor	12.4
4	malignant triton tumor	12.0
5	neurofibrosarcoma	11.9
6	childhood malignant schwannoma	11.9
7	adult malignant schwannoma	11.9
8	melanocytic psammomatous mpnst	11.2
9	malignant melanocytic neoplasm of the peripheral nerve sheath	11.2
10	malignant glandular tumor of peripheral nerve sheath	11.2
11	chromosome 17q11.2 deletion syndrome, 1.4-mb	11.1
12	neurofibromatosis	10.8
13	neurofibromatosis, type 1	10.6
14	neurofibroma	10.5
15	lucey-driscoll syndrome	10.4	MUC1, S100B
16	secondary pulmonary hemosiderosis	10.4	MUC1, S100B
17	sarcoma	10.4
18	melanoma	10.3
19	watson syndrome	10.3	NF1, NF2
20	uterine corpus leiomyomatosis	10.3	CDKN2A, MUC1, S100B
21	lupus - neurological sequelae	10.3	S100B, VIM
22	monostotic fibrous dysplasia	10.3	CDKN2A, MUC1, S100B
23	jejunal somatostatinoma	10.3	KIT, NF1, NF2
24	verrucous papilloma	10.3	KIT, NF1, SOX10
25	biliary papillomatosis	10.3	MUC1, S100B, VIM
26	subglottis verrucous carcinoma	10.3	MUC1, S100B, VIM
27	tricuspid valve prolapse	10.3	CDKN2A, EGFR, PDGFRA
28	behcet's syndrome arthropathy	10.3	MUC1, S100B, VIM
29	sternum cancer	10.3	MUC1, S100B, VIM
30	malignant epithelial mesothelioma	10.3	KIT, MUC1, PDGFRA
31	vulvar squamous papilloma	10.3	MUC1, S100B, VIM
32	bladder adenocarcinoma	10.3	CDKN2A, MUC1, VIM
33	avian influenza	10.3	CDKN2A, MUC1, VIM
34	plexiform neurofibroma	10.3
35	infiltrating lipoma	10.3	S100A1, S100B
36	ovarian insufficiency due to fsh resistance	10.3	MUC1, NF1, VIM
37	kidney clear cell sarcoma	10.3	EGFR, KIT, PDGFRA
38	gastrointestinal system cancer	10.3	MUC1, S100B, VIM
39	marfanoid hypermobility syndrome	10.3	KIT, MUC1, VIM
40	chondroblastoma	10.3	MUC1, NF2, VIM
41	stomach diverticulosis	10.3	KIT, S100B, VIM
42	subependymal glioma	10.3	MUC1, PDGFRA, VIM
43	vascular hemostatic disease	10.3	EGFR, NRG1, PDGFRA
44	extranodal nasal nk/t cell lymphoma	10.2	CDK4, CDKN2A, KIT
45	cervicitis	10.2
46	tumor of exocrine pancreas	10.2	CDKN2A, EGFR, MUC1, NF2
47	monckeberg arteriosclerosis	10.2	CDKN2A, NF1, NF2, SOX10
48	middle ear adenocarcinoma	10.2	EGFR, KIT, TOP2A
49	precursor t-lymphoblastic lymphoma/leukemia	10.2	EGFR, KIT, MUC1, S100B
50	distal trisomy 10q	10.2	NF2, SMARCB1

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

Sources:
²⁶GenomeRNAi, ⁴¹MGI
See all MalaCards sources

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

²⁶

id	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased proliferation	GR00094-A	9.9	NF2, SMARCB1, TP53
2	Decreased cell migration	GR00055-A-1	9.2	CDK4, EGFR, MUC1, NF1, NF2, VIM
3	Decreased viability	GR00381-A-1	9.1	CDKN2A, EGFR, KIT, NF1, PDGFRA, SMARCB1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	8.2	CDK4, EGFR, KIT, S100B, SMARCB1, SOX10

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

⁴¹ (show all 22)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	craniofacial	MP:0005382	9.0	EGFR, KIT, NF1, NF2, PDGFRA, SH3PXD2A
2	pigmentation	MP:0001186	8.5	CDK4, CDKN2A, EGFR, KIT, NF1, PDGFRA
3	skeleton	MP:0005390	8.4	CDKN2A, EGFR, HTRA1, KIT, NF1, NF2
4	renal/urinary system	MP:0005367	7.9	CDK4, CHGA, EGFR, KIT, NF1, NF2
5	liver/biliary system	MP:0005370	7.8	CDK4, CDKN2A, EGFR, KIT, NF1, NF2
6	respiratory system	MP:0005388	7.8	CDKN2A, EGFR, KIT, NF1, NF2, PDGFRA
7	neoplasm	MP:0002006	7.7	CDK4, CDKN2A, EGFR, KIT, NF1, NF2
8	vision/eye	MP:0005391	7.7	CDK4, CDKN2A, EGFR, HTRA1, KIT, NF1
9	integument	MP:0010771	7.6	CDK4, CDKN2A, EGFR, KIT, NF1, NF2
10	embryo	MP:0005380	7.4	CDK4, CDKN2A, EGFR, KIT, NF1, NF2
11	digestive/alimentary	MP:0005381	7.4	CDK4, CDKN2A, EGFR, KIT, NF1, PDGFRA
12	reproductive system	MP:0005389	7.3	CDK4, CDKN2A, CHGA, EGFR, KIT, NF2
13	endocrine/exocrine gland	MP:0005379	7.3	CDK4, CDKN2A, CHGA, EGFR, KIT, NF1
14	nervous system	MP:0003631	7.1	CDK4, CDKN2A, EGFR, KIT, NF1, NF2
15	normal	MP:0002873	7.0	ACTC1, CDK4, EGFR, KIT, NF1, PDGFRA
16	behavior/neurological	MP:0005386	6.8	CDK4, CDKN2A, KIT, NF1, NF2, PDGFRA
17	muscle	MP:0005369	6.4	ACTC1, CDK4, CDKN2A, EGFR, KIT, NF1
18	cellular	MP:0005384	6.2	ACTC1, CDK4, CDKN2A, EGFR, KIT, NF1
19	cardiovascular system	MP:0005385	5.6	ACTC1, CDK4, CDKN2A, CHGA, EGFR, HTRA1
20	mortality/aging	MP:0010768	5.6	ACTC1, CDK4, CDKN2A, CHGA, EGFR, KIT
21	growth/size/body region	MP:0005378	5.6	ACTC1, CDK4, CDKN2A, CHGA, EGFR, HTRA1
22	homeostasis/metabolism	MP:0005376	5.0	ACTC1, CDK4, CDKN2A, CHGA, EGFR, KIT

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

Sources:
¹BitterDB, ⁴ClinicalTrials, ¹⁰DGIdb, ¹⁴DrugBank, ²⁹HMDB, ³³IUPHAR, ⁴⁶NDF-RT, ⁵⁰Novoseek, ⁵⁶PharmGKB, ⁶⁸UMLS
See all MalaCards sources

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Mechlorethamine

approved

Phase 3, Phase 2, Phase 1

397

51-75-2

4033

Synonyms:

.Beta.,.beta.'-Dichlorodiethyl-N-methylamine

1, 5-Dichloro-3-methyl-3-azapentane hydrochloride

126-85-2 (N-oxide)

2,2'-Dichloro-N-me

2,2'-Dichloro-N-methyldiethylamine

2,2'-Dichlorodiethyl-methylamine

2,2'-dichloro-N-methyldiethylamine

2-Chloro-N-(2-chloroethyl)-N-methylethanamine

302-70-5 (N-oxide, hydrochloride)

51-75-2

55-86-7 (HYDROCHLORIDE)

AC1L1H9H

Antimit

BRN 0605323

BSPBio_001947

Bis(2-chloroethyl)methylamine

Bis(beta-chloroethyl) methylamine

Bis(beta-chloroethyl)methylamine

C07115

C5H11Cl2N

CCRIS 447

CHEBI:28925

CHEMBL427

CID4033

Carolysine

Caryolysin

Caryolysine

Chloramine (the nitrogen mustard)

Chlorethazine

Chlormethine

Chlormethine (INN)

Chlormethine [INN:BAN]

Chlormethinum [INN-Latin]

Cloramin

Clormetina

Clormetina [INN-Spanish]

D07671

DB00888

Di(2-chloroethyl)methylamine

Dichlor amine

Dichloren

DivK1c_000759

EINECS 200-120-5

ENT-25294

Embechine

Embichin

HMS1920J15

HMS2091B04

HMS502F21

HN-2

HN2

HSDB 5083

I14-8708

IBS-L0033631

IDI1_000759

KBio1_000759

KBio2_001369

KBio2_003937

KBio2_006505

KBio3_001447

KBioGR_001448

KBioSS_001369

LS-7559

MBA

Me chloroethamine

Mebichloramine

Mechlorethamine

Mechlorethanamine

Mechloroethamine

Mecloretamina

Mecloretamina [Italian]

Methylbis(2-chloroethyl)amine

Methylbis(beta-chloroethyl)amine

Methyldi(2-chloroethyl)amine

Mitoxine (*Hydrochloride*)

MolPort-001-785-592

Mustargen

Mustine

Mustine note

Mutagen

N,N-Bis(2-chloroethyl)-N-methylamine

N,N-Bis(2-chloroethyl)methylamine

N,N-Di(chloroethyl)methylamine

N-Lost

N-Methyl lost

N-Methyl-2,2'-dichlorodiethylamine

N-Methyl-bis(2-chloroethyl)amine

N-Methyl-bis(beta-chloroethyl)amine

N-Methyl-bis-chloraethylamin

N-Methyl-bis-chloraethylamin [German]

N-Methyl-lost

N-Methyl-lost [German]

N-methyl-bis(2-chloroethyl)amine

NCGC00091835-02

NCGC00091835-03

NCGC00091835-04

NCGC00091835-05

NCI60_041682

NINDS_000759

NSC762

Nitol (*Hydrochloride*)

Nitrogen mustard

Nitrogen mustard (HN-2)

Nitrogranulogen

SPBio_000496

SPECTRUM1500375

Spectrum2_000448

Spectrum3_000484

Spectrum4_000924

Spectrum5_001702

Spectrum_000889

Stickstofflost (*Hydrochloride*)

Stickstofflost (ebewe)

T 1024

T-1024

TL 146

UNII-50D9XSG0VR

beta,Beta'-dichlorodiethyl-N-methylamine

beta,beta'-Dichlorodiethyl-N-methylamine

mechlorethamine

thyldiethylamine

β,β'-dichlorodiethyl-N-methylamine

Ifosfamide

approved

Phase 3, Phase 2, Phase 1

400

3778-73-2

3690

Synonyms:

(+-)-Ifosfamid

(+-)-Ifosphamide

(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

(D,L)-Ifosfamide

(R,S)-Ifosphamide

(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

3,} 2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

36341-88-5

3778-73-2

84711-20-6

A 4942

AB00513932

AC-2113

AC1L1GHW

ASTA Z 4942

Ambap3778-73-2

Asta Z 4942

BPBio1_000865

BRN 0611835

BSPBio_000785

C07047

CAS-3778-73-2

CCRIS 352

CHEBI:5864

CHEMBL1024

CID3690

Cyfos

D00343

D007069

DB01181

EINECS 223-237-3

HMS1570H07

HMS2090M12

HMS2093N07

HSDB 7023

Holoxan

Holoxan 1000

I-Phosphamide

I06-0494

IFEX (TN)

Ifex

Ifosfamid

Ifosfamida

Ifosfamida [INN-Spanish]

Ifosfamide (JAN/USP/INN)

Ifosfamide Sterile

Ifosfamide [USAN:INN:BAN:JAN]

Ifosfamidum

Ifosfamidum [INN-Latin]

Ifosphamide

Ifsofamide

Iphosphamid

Iphosphamid(e)

Iphosphamide

Iso Endoxan

Iso-Endoxan

Isoendoxan

Isofosfamide

Isophosphamide

Isosfamide

LS-102

LS-99799

MJF 9325

MJF-9325

MLS002154021

Mitoxana

Mitoxana, Ifex, Ifosfamide

MolPort-003-666-704

N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide

N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

NCGC00016639-01

NCGC00179435-01

NCI-C01638

NCI60_000233

NPFAPI-04

NSC 109,724

NSC 109724

NSC-109,724

NSC-109724

NSC109,724

NSC109724

Naxamide

Prestwick0_000833

Prestwick1_000833

Prestwick2_000833

Prestwick3_000833

S1302_Selleck

SMR001233348

SPBio_002706

STL058690

UNII-UM20QQM95Y

WLN: T6NPOTJ AM2G BO B2G

Z 4942

Z-4942

Z4942

ifosfamide

isosfamide

{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,

Doxorubicin

approved, investigational

Phase 3, Phase 2, Phase 1

1751

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-Hydroxydaunomycin

14-Hydroxydaunorubicine

14-hydroxydaunomycin

14-hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

ADM

ADR

Adriablastin

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin Semiquinone

Adriamycin semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (TN)

Adriblastina (hydrochloride salt)

Aerosolized Doxorubicin

BPBio1_000502

BRD-K92093830-003-04-3

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

CCRIS 739

CHEBI:28748

CHEMBL179

CID31703

Caelyx

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

DOX-SL

Doxil

Doxo

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin HCl

Doxorubicin Hydrochloride

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicine

Doxorubicine [INN-French]

Doxorubicinum

Doxorubicinum [INN-Latin]

EINECS 245-495-6

FI 106

Farmablastina (hydrochloride salt)

HMS2089H06

HSDB 3070

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

LMPK13050001

LS-1029

LS-165655

MLS000759533

Myocet

NCI-C01514

NChemBio.2007.10-comp13

NDC 38242-874

NIOSH/JT9100000

NSC 123127

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

TLC D-99

ThermoDox

Triferric doxorubicin

UNII-80168379AG

adiblastine (hydrochloride salt)

adr iablatina (hydrochloride salt)

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

adriblatina (hydrochloride salt)

doxorubicin

nchembio809-comp5

Dacarbazine

approved, investigational

Phase 3, Phase 2, Phase 1

688

4342-03-4

5351166

Synonyms:

(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide

(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide

(Dimethyltriazeno)imidazolecarboxamide

37626-23-6

4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide

4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide

4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide

4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide

4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide

4-(Dimethyltriazeno)imidazole-5-c arboxamide

4-(Dimethyltriazeno)imidazole-5-carboxamide

4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide

4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide

4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide

4342-03-4

5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide

5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide

5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide

5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide

5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide

5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide

5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide

5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide

5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide

5-(Dimethyltriazeno)-4-imidazolecarboxamide

5-(Dimethyltriazeno)imidazole-4-carboxamide

5-(Dimethyltriazeno)imidazole-4-carboximide

5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide

5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide

94361-71-4

AC1NQXVV

AC1NS01W

AC1NS4BN

AI3-52825

BPBio1_000428

BRD-K35520305-001-07-8

BSPBio_000388

BSPBio_002091

Biocarbazin

Biocarbazine

Biocarbazine R

C6H10N6O

CAS-891986

CCRIS 190

CHEBI:4305

CHEMBL476

CID5281007

CID5351166

CID5353562

Carboxamide, Dimethyl Imidazole

D00288

D003606

D2390_SIGMA

D3634

DB00851

DIC

DTCI

DTIC

DTIC Dome

DTIC, DTIC-Dome, Dacarbazine

DTIC-Dome

DTICDome

DTIE

Dacarbazin

Dacarbazina

Dacarbazine

Dacarbazine (JAN/USP/INN)

Dacarbazine [USAN:INN:BAN:JAN]

Dacarbazino

Dacarbazino [INN-Spanish]

Dacarbazinum

Dacarbazinum [INN-Latin]

Dacatic

Decarbazine

Deticene

Di-me-triazenoimidazolecarboxamide

Di-methyl-triazenoimidazolecarboxamide

Dimethyl Imidazole Carboxamide

Dimethyl Triazeno Imidazole Carboxamide

Dimethyltriazenoimidazolecarboxamide

DivK1c_000326

Dtic-Dome

Dtic-Dome (TN)

Dtic-dome (tn)

EINECS 224-396-1

HE1150000

HMS1569D10

HMS2090A20

HMS2091I20

HMS501A08

HSDB 3219

I06-2280

I14-1659

ICDMT

ICDT

IDI1_000326

Imidazole Carboxamide

Imidazole Carboxamide, Dimethyl

Imidazole carboxamide

KBio1_000326

KBio2_001364

KBio2_003932

KBio2_006500

KBio3_001311

KBioGR_000896

KBioSS_001364

LS-119

MLS001332543

MLS001332544

MolPort-003-666-153

MolPort-003-846-120

MolPort-006-709-420

NCGC00016986-01

NCGC00091861-01

NCGC00091861-02

NCGC00091861-03

NCGC00091861-04

NCI-C04717

NCI60_004053

NCIMech_000261

NINDS_000326

NIOSH/HE1150000

NPFAPI-05

NSC 45388

NSC-45388

NSC45388

Prestwick0_000574

Prestwick1_000574

Prestwick2_000574

Prestwick3_000574

Prestwick_904

S1221_Selleck

SMP2_000251

SMR000857131

SPBio_001075

SPBio_002607

SPECTRUM1500218

ST51014976

Spectrum2_001148

Spectrum3_000366

Spectrum4_000308

Spectrum5_000823

Spectrum_000884

UNII-7GR28W0FJI

WLN: T5M CNJ DVZ ENUNN1&1

dacarbazine

Carboplatin

approved

Phase 3

2050

41575-94-4

10339178, 498142, 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

Carbopaltin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Cbdca

Cyclobutane-1,1-dicarboxylate

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

EU-0100230

Ercar

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

IUPAC: Azane

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

JM 8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

LS-117689

Lopac-C-2538

Lopac0_000230

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

NINDS_000892

NSC 201345

NSC 241240

NSC-241240

NSC201345

NSC241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

Platinum(II), (1, 1-cyclobutanedicar

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Platinum, {diammine[1,1-cyclobut

S1215_Selleck

SPBio_000716

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

Spectrum_001529

UNII-BG3F62OND5

azanide

carboplatin

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

cyclobutane-1,1-dicarboxylic acid

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

platinum(2+)

Lenograstim

approved

Phase 3, Phase 2

1220

135968-09-1

Synonyms:

G-CSF (CHO cell derived)

Glycosylated recombinant G-CSF

Glycosylated recombinant granulocyte colony stimulating factor

Granulocyte colony stimulating factor 3 (CHO cell derived)

Granulocyte colony-stimulating factor lenograstim

Lenograstim (genetical recombination)

Lenograstim rDNA

Cyclophosphamide

approved, investigational

Phase 3, Phase 2

2935

50-18-0, 6055-19-2

2907

Synonyms:

(+-)-Cyclophosphamide

(-)-Cyclophosphamide

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

ASTA

ASTA B518

Anhydrous cyclophosphamide

Asta B 518

B 518

B-518

BRN 0011744

BSPBio_002099

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

CID2907

CPA

CTX

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

Clafen

Claphene

Cycloblastin

Cyclophosphamid

Cyclophosphamide

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide anhydrous

Cyclophosphamide, (+-)-Isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

EU-0100238

Endoxan

Endoxan R

Endoxan-Asta

Endoxana

Endoxanal

Endoxane

Enduxan

Genoxal

HMS2090A12

HSDB 3047

Hexadrin

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

LS-1302

LS-99787

Ledoxina

Lopac-C-0768

Lopac0_000238

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI-C04900

NCI60_002097

NINDS_000246

NSC 26271

NSC-26271

NSC26271

NSC273033

NSC273034

Neosar

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra Waste Number U058

Rcra waste number U058

Revimmune

S1217_Selleck

SK 20501

SPBio_001071

STK177249

STOCK2S-91217

Semdoxan

Sendoxan

Senduxan

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

Spectrum_000858

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

cyclophosphamide

Vincristine

approved, investigational

Phase 3

922

2068-78-2, 57-22-7

5978

Synonyms:

22-Oxovincaleukoblastin

22-Oxovincaleukoblastine

28379-27-3

57-22-7

AC1L1LJC

C07204

C46H56N4O10

CCRIS 5763

CHEBI:28445

CID5978

D08679

DB00541

EINECS 200-318-1

HMS2090E19

HSDB 3199

Indole alkaloid

LCR

LS-228

Leurocristine

Lilly 37231 (1:1 sulfate salt)

Liposomal Vincristine

Marqibo

NCGC00163700-01

NCI-C04864

NCI60_026703

NSC-67574

Onco TCS

Oncovin

Oncovin (1:1 sulfate salt)

Oncovine

Tecnocris

Tecnocris (TN)

UNII-5J49Q6B70F

VCR

VIN

Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine

Vincasar

Vincasar (1:1 sulfate salt)

Vincasar PFS

Vincrex

Vincrex (1:1 sulfate salt)

Vincristin

Vincristina

Vincristina [DCIT]

Vincristine (INN)

Vincristine Sulfate

Vincristine Sulfate PFS

Vincristine [INN:BAN]

Vincristinum

Vincristinum [INN-Latin]

Vincrstine

Vincrystine

Vinkristin

Z-D-Val-Lys(Z)-OH

vincristine

Dactinomycin

approved

Phase 3

50-76-0

2019, 457193

Synonyms:

(- )-actinomycin d

(-)-actinomycin d

-pentone

01815_FLUKA

1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine

2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

50-76-0

A1410_SIGMA

A4262_SIGMA

A9415_SIGMA

AC1L1CQX

AC1L9W52

ACT

ACT D

ACTINOMYCIN D

ACTINOMYCIN D AMP

ACTINOMYCIN-D

ACTO-D

ACon0_000471

ACon1_001004

AD (VAN)

AI3-26374

ActD

Actactinomycin A IV

Actactinomycin a Iv

Actinomycin 11 Cosmegen

Actinomycin 11 cosmegen

Actinomycin 7

Actinomycin A IV

Actinomycin Aiv

Actinomycin C (sub1)

Actinomycin C(sub1)

Actinomycin C1

Actinomycin D

Actinomycin D (JP15)

Actinomycin D deriv. of 3H-phenoxaocardazine

Actinomycin D, sodium deoxyribonucleic acid complex

Actinomycin I

Actinomycin I (sub1)

Actinomycin I(sub 1)

Actinomycin I(sub1)

Actinomycin I1

Actinomycin IV

Actinomycin Iv

Actinomycin X 1

Actinomycin X1

Actinomycin iv

Actinomycin-(threo-val-pro-sar-meval)

Actinomycin-?IV

Actinomycin-[threo-val-pro-sar-meval]

Actinomycindioic D Acid, Dilactone

Actinomycindioic D acid, dilactone

Acto-D

Antibiotic From Streptomyces Parvullus

Antibiotic from Streptomyces parvullus

BCBcMAP01_000155

BRD-A42383464-001-02-2

Bio1_000342

Bio1_000831

Bio1_001320

C06770

C62H86N12O16

CBiol_002056

CCRIS 9

CHEBI:123721

CHEBI:27666

CHEMBL1554

CHEMBL427947

CID2019

CID457193

COSMEGEN (TN)

CPD000469227

Chounghwamycin B

Cosmegen

D Actinomycin

D00214

DACTINOMYCIN

DB00970

DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA

Dactinomicina

Dactinomicina [INN-Spanish]

Dactinomycin

Dactinomycin (USP)

Dactinomycin D

Dactinomycin [USAN:BAN]

Dactinomycine

Dactinomycine [INN-French]

Dactinomycinum

Dactinomycinum [INN-Latin]

Dilactone Actinomycin D Acid

Dilactone Actinomycindioic D Acid

Dilactone actin omycindioic D acid

Dilactone actinomycin D acid

Dilactone actinomycindioic D acid

EINECS 200-063-6

FT-0080366

GNF-PF-1977

HBF 386

HBF 386 Meractinomycin

HBF 386 meractinomycin

HMS2052O17

HSDB 3220

LMPK14000005

LS-142

Lyovac Cosmegen

Lyovac cosmegen

MEGxm0_000350

MLS001424196

Meractinomycin

MolPort-001-739-741

MolPort-003-925-177

NCGC00025059-02

NCGC00090796-01

NCGC00161622-01

NCGC00161622-02

NCGC00169767-01

NCI-C04682

NCI60_030539

NP-005932

NSC 3053

NSC-3053

NSC191297

NSC3053

Neuro_000003

Oncostatin K

Oxamide

PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA

SAM001246846

SMP1_000005

SMR000469227

UNII-1CC1JFE158

UPCMLD-DP055

UPCMLD-DP055:001

UPCMLD-DP055:002

WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1

X 97

actd

actinomycin D

actinomycin cl

actinomycin x i

actinomyein-theo-val-pro-sar-meval

dactinomyein d

o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine

Etoposide

approved

Phase 3, Phase 2

1269

33419-42-0

36462

Synonyms:

(-)-Etoposide

121471-01-0

136598-18-0

201594-04-9

33419-42-0

35317-32-9

4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside

4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin

4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside

4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside

51854-34-3

76576-58-4

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

AB00438905

AC1L1FN8

AC1L1VT3

AC1L6246

AC1NR4OG

AC1O4WGG

AC1O7M1N

AC1Q47JJ

Ambap33419-42-0

BPBio1_000673

BRD-K37798499-001-02-5

BSPBio_000611

Bio1_000489

Bio1_000978

Bio1_001467

C01576

CCRIS 2392

CHEBI:4911

CHEBI:588795

CHEMBL44657

CID11758093

CID284997

CID3310

CID36462

CID5284558

CID6419930

CID6610299

CPD000112002

D00125

DB00773

DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,

Demethyl Epipodophyllotoxin Ethylidine Glucoside

Demethyl-epiodophyllotoxin ethylidene glucoside

Demethylepipodophyllotoxin-beta-D-ethylideneglucoside

E0675

E1383_SIGMA

EINECS 251-509-1

EPE

EPEG

ETOP

Epipodophyllotoxin

Epipodophyllotoxin VP-16213

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

Eposide

Eposin

Eposin, Vepesid, VP-16, Toposar, Etoposide

Etopol

Etopophos

Etopophos (phosphate salt)

Etoposid

Etoposide

Etoposide (JP15/USP/INN)

Etoposide (VP16)

Etoposide [USAN:INN:BAN:JAN]

Etoposido

Etoposido [INN-Spanish]

Etoposidum

Etoposidum [INN-Latin]

Etosid

HMS1569O13

HMS2052N05

HMS2089F14

HSDB 6517

I06-0248

KBioSS_002410

LS-1214

Lastet

MLS000049957

MLS001074951

MLS001424283

MLS002153463

MLS002207239

MLS002222184

MolPort-003-983-431

MolPort-004-905-001

MolPort-004-955-161

NCGC00025056-02

NChemBio.2007.10-comp19

NK 171

NSC 141540

NSC-141540

NSC141540

Prestwick0_000396

Prestwick1_000396

Prestwick2_000396

Prestwick3_000396

Prestwick_211

S1225_Selleck

SAM001246880

SMR000112002

SPBio_002532

ST056353

Toposar

UNII-6PLQ3CP4P3

VP 16

VP 16 (pharmaceutical)

VP 16-213

VP 16213

VP-16

VP-16-213

VePESID (TN)

VePesid

Vepesid

Vepesid J

Vepeside

ZINC03830818

ZINC03938684

Zuyeyidal

etoposide

nchembio.573-comp8

nchembio873-comp2

trans-Etoposide

Epirubicin

approved

Phase 3

394

56420-45-2

41867

Synonyms:

(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside

(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside

(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione

4'-Epi-DXR

4'-Epiadriamycin

4'-Epidoxorubicin

4'-epi-DX

4'-epi-Doxorubicin

4'-epidoxorubicin

4-Epidoxorubicin

56390-09-1

56390-09-1 (hydrochloride)

56420-45-2

57918-25-9

AC1L26NP

AC1Q6JIV

BRN 1445813

C11230

C27H29NO11

CCRIS 2261

CHEBI:47898

CHEMBL417

CID41867

D07901

DB00445

Ellence

Epi-DX

Epi-Dx

Epiadriamycin

Epidoxorubicin

Epirubicin

Epirubicin (INN)

Epirubicin [INN:BAN]

Epirubicina

Epirubicina [INN-Spanish]

Epirubicina [Spanish]

Epirubicine

Epirubicine [French]

Epirubicine [INN-French]

Epirubicinum

Epirubicinum [INN-Latin]

Epirubicinum [Latin]

Farmorubicin (TN)

HSDB 6962

IMI 28

LS-187190

LS-93992

MLS000759412

NChemBio.2007.10-comp15

NSC 256942

NSC-256942

NSC256942

Pharmorubicin Pfs

Pidorubicin

Pidorubicina

Pidorubicina [INN-Spanish]

Pidorubicine

Pidorubicine [INN-French]

Pidorubicinum

Pidorubicinum [INN-Latin]

Ridorubicin

SMR000466308

Triferric doxorubicin

UNII-3Z8479ZZ5X

WP 697

Trabectedin

approved, investigational

Phase 3, Phase 2

114899-77-3

108150

Synonyms:

ET-743

ET743

Ecteinascidin

Ecteinascidin 743

NSC 684766

Gemcitabine

approved

Phase 3, Phase 2, Phase 1

2018

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DiF-dC

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFDC

DFdC

DFdCyd

Folfugem

GEO

Gamcitabine

GemLip

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabinum

Gemcitabinum [INN-Latin]

Gemtro

Gemzar

Gemzar (hydrochloride)

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY-188011

LY188011

NCGC00168784-01

NChemBio.2007.10-comp25

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

ZINC18279854

Zefei

gemcitabine

nchembio.573-comp7

nchembio.90-comp2

Cyproheptadine

approved

Phase 3

129-03-3

2913

Synonyms:

1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine

1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine

1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine

129-03-3

4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine

4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine

4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene

4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine

4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine

41354-29-4

5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene

5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene

5-20-08-00500 (Beilstein Handbook Reference)

AC1L1ER8

AKOS004119847

Axoprol

BIDD:GT0324

BPBio1_000096

BPBio1_000155

BRD-K28143534-001-01-4

BRD-K28143534-003-03-6

BRN 1685976

BSPBio_000086

Biomol-NT_000131

C06935

CAS-969-33-5

CCRIS 5232

CHEBI:4046

CHEMBL516

CID2913

CYPROHEPTADINE

Ciproheptadina

Ciproheptadina [INN-Spanish]

Ciprovit

Ciprovit (TN)

Cypoheptadine

Cyproheptadiene

Cyproheptadin

Cyproheptadine

Cyproheptadine (INN)

Cyproheptadine Hcl

Cyproheptadine [INN:BAN]

Cyproheptadinum

Cyproheptadinum [INN-Latin]

D07765

DB00434

Dibenzosuberonone/Cyproheptadine

Dihexazin

Dronactin

EINECS 204-928-9

Eiproheptadine

Glutodina

HMS2090P20

HSDB 3048

L001016

LS-114933

Lopac-C-6022

Lopac0_000246

MK 141

MolPort-002-507-777

NCGC00015252-01

NCGC00015252-02

NCGC00015252-03

NCGC00015252-09

NCGC00024293-02

NCGC00024293-04

NCGC00024293-05

Oprea1_498140

PDSP1_001229

PDSP2_001213

Periactin

Periactine

Periactinol

Prestwick0_000103

Prestwick1_000103

Prestwick2_000103

Prestwick3_000103

SPBio_002025

STK802098

Tocris-0996

UNII-2YHB6175DO

Viternum

nchembio.559-comp10

Histamine

approved, investigational

Phase 3

1050

75614-87-8, 51-45-6

774

Synonyms:

.beta.-Imidazolyl-4-ethylamine

1H-Imidazole-4-ethanamine

1H-Imidazole-5-ethanamine

1avn

1qft

2-(1H-Imidazol-4-yl)ethanamine

2-(1H-Imidazol-4-yl)ethylamine

2-(1H-Imidazol-5-yl)ethanamine

2-(1H-Imidazol-5-yl)ethylamine

2-(1H-imidazol-4-yl)ethan-1-amine

2-(1H-imidazol-5-yl)ethanamine

2-(3H-Imidazol-4-yl)-ethylamine

2-(4-Imidazolyl)ethanamine

2-(4-Imidazolyl)ethylamine

2-(4-imidazolyl)ethylamine

2-Imidazol-4-yl-Ethylamine

2-Imidazol-4-ylethylamine

2-[4-Imidazolyl]ethylamine

4-(2-Aminoethyl)-1H-imidazole

4-(2-Aminoethyl)imidazole

4-Imidazoleethylamine

4-imidazoleethylamine

5-Imidazoleethylamine

5-imidazoleethylamine

51-45-6

53290_FLUKA

64422-25-9

924364-91-0

AC-13185

AC1L19ZT

AC1Q54BV

AC1Q54BW

AKOS000274386

ALBB-005968

BCBcMAP01_000250

BSPBio_001117

BSPBio_002124

Bio1_000487

Bio1_000976

Bio1_001465

Bio2_000389

Bio2_000869

C00388

CCRIS 6535

CHEBI:18295

CHEMBL90

CID774

D08040

DivK1c_000308

EINECS 200-100-6

Eramin

Ergamine

Ergotidine

F411C768-A159-4FC0-A195-291A08BB03AA

Free histamine

H7125_SIGMA

HMS1362G19

HMS1792G19

HMS1990G19

HSDB 3338

HSM

Histamine

Histamine (DCF)

Histamine Base

Histamine [USAN]

Histamine, Free Base

Histaminum

Histaminum (TN)

IDI1_000308

IDI1_002144

Imidazole-4-ethylamine

Istamina

Istamina [Italian]

KBio1_000308

KBio2_000457

KBio2_001325

KBio2_003025

KBio2_003893

KBio2_005593

KBio2_006461

KBio3_000853

KBio3_000854

KBio3_001344

KBioGR_000457

KBioGR_001580

KBioSS_000457

KBioSS_001325

L-Histamin base

L-Histamine

L-histamine

L000292

LS-75835

Lopac-H-7250

Lopac0_000595

MLS000069447

MolPort-001-785-597

MolPort-002-042-264

NCGC00015513-01

NCGC00015513-08

NCGC00093371-02

NCGC00093371-03

NCGC00093371-04

NCGC00093371-05

NINDS_000308

NSC 33792

NSC33792

SDCCGMLS-0066601.P001

SMP1_000151

SMR000059091

SPBio_000729

ST073926

STK346752

STOCK5S-55669

Spectrum2_000665

Spectrum3_000452

Spectrum4_000960

Spectrum5_000796

Spectrum_000845

Theramine

UNII-820484N8I3

WLN: T5M CNJ D2Z

ZERO/004089

[3H]histamine

b-Imidazolyl-4-ethylamine

beta-Aminoethylglyoxaline

beta-Aminoethylimidazole

beta-Aminothethylglyoxaline

beta-Imidazolyl-4-ethylamine

beta-aminoethylglyoxaline

beta-aminoethylimidazole

beta-aminothethylglyoxaline

bmse000744

histamine

nchembio.87-comp54

nchembio714-comp1

Doxil

Approved June 1999

Phase 3, Phase 2, Phase 1

1751

31703

Synonyms:

Dox-SL

Doxil

Evacet

LipoDox

Pegylated Liposomal Doxorubicin Hydrochloride

liposomal doxorubicin

Docetaxel

approved, investigational, Approved May 1996

Phase 3, Phase 1, Phase 2

1967

114977-28-5

148124, 9877265

Synonyms:

(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate

(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate

01885_FLUKA

114977-28-5

4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate

AC-383

AC1L3WHJ

ANX-514

BIND-014

C11231

CHEBI:4672

CHEMBL92

CID148124

D07866

DB01248

Docetaxel

Docetaxel (INN)

Docetaxel anhydrous

Docetaxel, Trihydrate

EmDOC

HMS2089K08

InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5

MolPort-003-847-005

N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel

N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol

N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel

N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol

N-debenzoyl-N-Boc-10-deacetyl taxol

NSC-628503

PSMA-targeted docetaxel nanoparticle

RP-56976

SDP-014

TXL

Taxotere

Taxotere (TN)

Taxotere(R)

XRP-6976L

docetaxel

docetaxel 114977-28-5

nchembio.188-comp8

nchembio.2007.34-comp7

nchembio.573-comp11

nchembio853-comp8

Antibiotics, Antitubercular

Phase 3, Phase 2, Phase 1

7180

Anti-Bacterial Agents

Phase 3, Phase 2, Phase 1

11226

Antineoplastic Agents, Alkylating

Phase 3, Phase 2, Phase 1

4603

Isophosphamide mustard

Phase 3, Phase 2, Phase 1

400

Topoisomerase Inhibitors

Phase 3, Phase 2, Phase 1

5069

Alkylating Agents

Phase 3, Phase 2, Phase 1

4827

Protein Kinase Inhibitors

Phase 2, Phase 3, Phase 1

3689

Imatinib Mesylate

Phase 2, Phase 3, Phase 1

600

123596

Antiviral Agents

Phase 3, Phase 2, Phase 1

9967

Nucleic Acid Synthesis Inhibitors

Phase 3

4962

Anti-Infective Agents

Phase 3, Phase 1, Phase 2

22062

Antineoplastic Agents, Phytogenic

Phase 3, Phase 2

5602

Antimitotic Agents

Phase 3, Phase 2, Phase 1

5657

Antirheumatic Agents

Phase 3, Phase 1

10956

Immunosuppressive Agents

Phase 3, Phase 1, Phase 2

13086

Etoposide phosphate

Phase 3, Phase 2

1269

Antimetabolites, Antineoplastic

Phase 3, Phase 2, Phase 1

7361

Antimetabolites

Phase 3, Phase 2, Phase 1

12054

Neurotransmitter Agents

Phase 3

18340

Serotonin

Phase 3

3627

50-67-9

5202

Synonyms:

3-(2-Aminoethyl)-1H-indol-5-ol

3-(2-Aminoethyl)indol-5-ol

3-(b-Aminoethyl)-5-hydroxyindole

5-HT

5-HTA

5-Hydroxy-3-(b-aminoethyl)indole

5-Hydroxy-tryptamine

5-Hydroxyltryptamine

5-Hydroxytriptamine

5-Hydroxytryptamine

Antemovis

DS substance

Enteramin

Enteramine

Histamine Phosphate

Phase 3

1049

51-74-1

65513

Synonyms:

1H-Imidazole-4-ethanamine, phosphate (1:2)

2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)

4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)

4-(2-Aminoethyl)imidazole di-acid phosphate

4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate

51-74-1

53623-99-7

74-56-6

AC1L23E4

CID65513

D04445

DB00667

EINECS 200-118-4

H0147

Histamine acid phosphate

Histamine biphosphate

Histamine dihydrogen phosphate

Histamine diphosphate

Histamine phosphate (1:2)

Histamine phosphate (TN)

Histamine phosphate (USP)

Histamine phosphate [USP]

Histamine positive

LS-78569

UNII-QWB37T4WZZ

Serotonin Antagonists

Phase 3

1409

Serotonin Agents

Phase 3

3156

Dermatologic Agents

Phase 3

5806

Histamine H1 Antagonists

Phase 3

791

Antipruritics

Phase 3

841

Anti-Allergic Agents

Phase 3

1522

Histamine Antagonists

Phase 3

961

Gastrointestinal Agents

Phase 3

8402

Temozolomide

approved, investigational

Phase 2, Phase 1

711

85622-93-1

5394

Synonyms:

3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide

3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide

3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide

3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide

3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide

3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide

3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide

3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one

8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one

85622-93-1

AC-758

AC1L1K9B

BIDD:GT0204

BRN 5547136

Bio-0147

C047246

C6H6N6O2

CCRG 81045

CCRG-81045

CCRIS 8996

CHEBI:153686

CHEMBL810

CID5394

CPD000466338

D06067

DB00853

Essex brand of temozolomide

HMS2051O12

HMS2090B08

I06-0149

I14-1943

LS-80558

M B 39831

M & B 39831

M&B 39831

M&B-39831

M-39831

MB 39831

MLS000759447

MLS001424028

MLS002701861

Methazolastone

NCGC00167429-01

NCGC00167429-02

NCI60_003316

NSC 362856

NSC-362856

NSC362856

SAM001246636

SMR000466338

STK623541

Sch 52365

Sch-52365

Schering brand of temozolomide

Schering-Plough brand of temozolomide

TL8005593

TMZ

TMZ-Bioshuttle

Temodal

Temodal (TN)

Temodar

Temozolamide

Temozolodida

Temozolodida [Spanish]

Temozolomid

Temozolomida

Temozolomide (JAN/USAN/INN)

Temozolomide [INN:BAN]

Temozolomidum

Temozolomidum [Latin]

Témozolomide

UNII-YF1K15M17Y

ZINC01482184

m & b 39831

temozolomide

Sunitinib

approved, investigational

Phase 2

510

341031-54-7, 557795-19-4

5329102

Synonyms:

(2S)-2-hydroxybutanedioic acid

1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)

326914-13-0

341031-54-7

5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE

557795-19-4

AC1NS62J

AC1O5CMQ

AKOS005145765

Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)

CHEBI:38940

CHEBI:550864

CHEMBL1567

CHEMBL535

CID5329102

CID6456015

D06402

D08552

DB01268

DB07417

EN002687

FT-0083555

FT-0083556

I01-1229

K00588a

KS-5022

LS-186078

LS-187023

LS-187648

MolPort-003-986-763

N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate

N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

NCGC00164631-01

NSC736511

NSC750690

PDGF TK antagonist

PHA-290940AD

PNU-290940AD

S1042_Selleck

ST51053712

SU 011248

SU 11248

SU-010398

SU-011248 L-malate salt

SU-11248

SU-11248 L-malate salt

SU-11248J

SU-12662

SU010398

SU011248

SU011248 L-malate salt

SU11248

Su-011248

Sunitanib

Sunitinib

Sunitinib (INN)

Sunitinib (free base)

Sunitinib malate

Sunitinib malate (JAN/USAN)

Sunitinib malate [USAN]

Sunitinibum

Sutent

Sutent (TN)

Sutent, SU-11248

TL8002546

UNII-LVX8N1UT73

UNII-V99T50803M

sunitinib

sunitinibum

Romidepsin

approved, investigational

Phase 2

128517-07-7

5352062

Synonyms:

(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone

(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

128517-07-7

AC1NS1N3

Antibiotic FR 901228

C087123

C24H36N4O6S2

CHEBI:61080

CHEMBL343448

CID5352062

Chromadax

Chromadax (TN)

Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3?5)-disulfide"

D06637

FK 228

FK-228

FK-901228

FK228

FR 901228

FR-901228

FR901228

HDInhib_000006

Istodax

L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide

LS-161318

NSC 630176

NSC-630176

NSC630176

Probes1_000153

Probes2_000337

Romidepsin

Romidepsin (USAN)

chromodax

istodax

nchembio.313-comp2

Sorafenib

approved, investigational

Phase 2

700

284461-73-0

216239, 406563

Synonyms:

284461-73-0

4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide

4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide

4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate

4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide

4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide

4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide

4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide

4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE

AB1004622

AC-1674

AC1L50CF

BAX

BAY 43-9006

BAY 43-9006 (free base)

BAY 43-9006 tosylate salt

BAY 439006

BAY 54-9085 (tosylate salt)

BAY-43-0006

BAY-43-9006

BAY-54-9085

BAY43-9006

BRD-K23984367-001-01-8

Bio-0100

CHEBI:47228

CHEBI:50924

CHEMBL1336

CID216239

D08524

DB00398

DB07438

EN002709

I06-0856

K00597a

Kinome_766

LS-186067

LS-187021

LS-187788

MolPort-003-850-270

N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea

N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea

N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

NCGC00167488-01

NSC-724772

NSC747971

Nexavar

STK627350

Sorafenib

Sorafenib (INN)

Sorafenib [INN]

Sorafenib tosylate

Sorafenibum

UNII-9ZOQ3TZI87

ZINC01493878

nchembio.117-comp17

sorafenib

sorafenibum

Interventional clinical trials:

(show top 50) (show all 77)

id	Name	Status	NCT ID	Phase
1	Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma	Unknown status	NCT00346164	Phase 3
2	Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma	Unknown status	NCT00334854	Phase 3
3	Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma	Completed	NCT00003212	Phase 3
4	Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma	Completed	NCT00003052	Phase 3
5	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma	Completed	NCT00002764	Phase 3
6	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma	Completed	NCT00002641	Phase 3
7	Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis	Completed	NCT00091351	Phase 3
8	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma	Completed	NCT00061984	Phase 3
9	Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma	Completed	NCT00002898	Phase 3
10	Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy	Recruiting	NCT01710176	Phase 3
11	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery	Recruiting	NCT02180867	Phase 2, Phase 3
12	Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma	Active, not recruiting	NCT00423618	Phase 3
13	Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors	Terminated	NCT00427583	Phase 2, Phase 3
14	Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma	Terminated	NCT01189253	Phase 2, Phase 3
15	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3
16	Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma	Unknown status	NCT00003718	Phase 2
17	Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma	Unknown status	NCT00410462	Phase 2
18	S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor	Completed	NCT00068367	Phase 2
19	Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors	Completed	NCT00304083	Phase 2
20	Sorafenib and Dacarbazine in Soft Tissue Sarcoma	Completed	NCT00837148	Phase 2
21	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma	Completed	NCT01154452	Phase 1, Phase 2
22	Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma	Completed	NCT00245102	Phase 2
23	Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma	Completed	NCT00112463	Phase 2
24	Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma	Completed	NCT00949325	Phase 1, Phase 2
25	Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases	Completed	NCT00154388	Phase 2
26	Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma	Completed	NCT00041249	Phase 2
27	Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma	Completed	NCT00041236	Phase 2
28	STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma	Completed	NCT00006357	Phase 1, Phase 2
29	Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma	Completed	NCT00003939	Phase 2
30	BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors	Completed	NCT00526149	Phase 2
31	Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas	Completed	NCT00474994	Phase 2
32	Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma	Completed	NCT00053794	Phase 2
33	Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma	Completed	NCT00031915	Phase 2
34	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Completed	NCT00589784	Phase 2
35	A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery	Recruiting	NCT02691026	Phase 2
36	PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors	Recruiting	NCT02584647	Phase 1, Phase 2
37	A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma	Recruiting	NCT02601950	Phase 2
38	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma	Recruiting	NCT02601209	Phase 1, Phase 2
39	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
40	Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma	Recruiting	NCT01532687	Phase 2
41	Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma	Recruiting	NCT02584309	Phase 2
42	Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma	Recruiting	NCT01883518	Phase 1, Phase 2
43	SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors	Active, not recruiting	NCT01661283	Phase 2
44	SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)	Active, not recruiting	NCT02008877	Phase 1, Phase 2
45	Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma	Active, not recruiting	NCT02452554	Phase 2
46	Trial of Dasatinib in Advanced Sarcomas	Active, not recruiting	NCT00464620	Phase 2
47	Alisertib in Treating Patients With Advanced or Metastatic Sarcoma	Active, not recruiting	NCT01653028	Phase 2
48	Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma	Active, not recruiting	NCT01614795	Phase 2
49	Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors	Not yet recruiting	NCT02986919	Phase 2
50	Phase II Pediatric Study With Dabrafenib in HGG Patients	Not yet recruiting	NCT02684058	Phase 2

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

Sources:
³⁶MalaCards
See all MalaCards sources

MalaCards organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

³⁶

Lung, Breast, Kidney, Bone, Cervix, Prostate, Liver

Publications for Malignant Peripheral Nerve Sheath Tumor

Sources:
⁵⁷PubMed
See all MalaCards sources

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 552)

id	Title	Authors	Year
1	Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. (27706810)	Ikuta K.... Nishida Y.	2017
2	Acute hydrocephalus due to a primary malignant peripheral nerve sheath tumor of the cervicothoracic junction: A case report and review of the literature. (28502561)	Samanci Y.... Celik S.E.	2017
3	Malignant peripheral nerve sheath tumor in three patients of advanced age. (26713647)	Wruhs M.... Steiner A.	2016
4	Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database. (27158754)	Le Guellec S.... Coindre J.M.	2016
5	Primary Intraosseous Malignant Peripheral Nerve Sheath Tumor of theA Medial Cuneiform: A Case Report and Review of the Literature. (27449524)	Muthusamy S.... Temple H.T.	2016
6	Synchronous Malignant Peripheral Nerve Sheath Tumor and Adenocarcinoma of the Prostate: Case Report and Literature Review. (27872787)	Ferakis N.... Farmakis A.	2016
7	CT, MRI, and (18)F-FDG PET/CT findings of malignant peripheral nerve sheath tumor of the head and neck. (28068826)	Kim H.Y.... Kim S.T.	2016
8	Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma. (27655679)	Shurell E.... Dry S.M.	2016
9	Metastatic Malignant Peripheral Nerve Sheath Tumor. (27349784)	Soares do Brito J.... Portela J.	2016
10	Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. (26840085)	Varin J.... Parfait B.	2016
11	BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells. (28055968)	Graham C.D.... Roth K.A.	2016
12	Malignant Peripheral Nerve Sheath Tumor of the Jugular Foramen. (27223674)	Puricelli M.D.... Lin J.	2016
13	Composite pheochromocytoma with a malignant peripheral nerve sheath tumor: Case report and review of the literature. (27338175)	Namekawa T.... Ichikawa T.	2016
14	Malignant peripheral nerve sheath tumor coexisting with congenital melanocytic nevus in an elderly man. (26897251)	Park J.K.... Hasegawa T.	2016
15	Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. (27588404)	Shurell E.... Eilber F.C.	2016
16	Malignant Peripheral Nerve Sheath Tumor of the Infraorbital Nerve. (27162577)	D'Addino J.L.... de Gordon M.J.	2016
17	Malignant peripheral nerve sheath tumor with extensive osteosarcomatous and chondrosarcomatous differentiation: A case report. (27388706)	Meshikhes A.W.... Amr S.S.	2016
18	Spinal Intradural Primary malignant peripheral nerve sheath tumor with leptomeningeal seeding: case report and literature review. (27593814)	Baharvahdat H.... Baradaran A.	2016
19	Malignant Peripheral Nerve Sheath Tumor of the Liver. (26831017)	Kakizaki S.... Yamada M.	2016
20	Malignant peripheral nerve sheath tumor in the cervical spine with multiple nevus cell nevi. (26740424)	Asano K.... Matsuyama Y.	2016
21	Palliative Epineurotomy for Focal Radial Malignant Peripheral Nerve Sheath Tumor in a Dog. (27487351)	Gibson A.D.... Lafuente P.	2016
22	Radiological findings of malignant peripheral nerve sheath tumor: reports of six cases and review of literature. (27159980)	Yu Y.H.... Chen M.X.	2016
23	Medullary metastasis of a malignant peripheral nerve sheath tumor: A case report. (27588138)	Hagi T.... Sudo A.	2016
24	Malignant Peripheral Nerve Sheath Tumor of Prostate: A Rare Case Report and Literature Review. (27872789)	Hsieh K.L.... Liao A.C.	2016
25	Malignant Peripheral Nerve Sheath Tumor. (27591499)	James A.W.... Eilber F.C.	2016
26	A Case of Occipital Malignant Peripheral Nerve Sheath Tumor with Neurofibromatosis Type 1. (27628604)	Hanai U.... Matsumae M.	2016
27	Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation. (26859681)	Hirbe A.C.... Gutmann D.H.	2016
28	Primary hepatic malignant peripheral nerve sheath tumor successfully treated with combination therapy: a case report and literature review. (27904856)	Jung H.I.... Bae S.H.	2016
29	Intraneural ganglion cyst of the ulnar nerve at the elbow masquerading as a malignant peripheral nerve sheath tumor. (27593718)	Mobbs R.J.... Simon N.	2016
30	Orbital Malignant Peripheral Nerve Sheath Tumor With Heterologous Elements in a 15-Year-Old Girl. (27112168)	Kiratli H.... Orhan D.	2016
31	An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors. (27333032)	Patel A.V.... Ratner N.	2016
32	Malignant peripheral nerve sheath tumor in the paraspinal region mimicking a benign peripheral nerve sheath tumor: a case report. (27679432)	Pan W.... Ye Z.	2016
33	Malignant peripheral nerve sheath tumor presenting as orbito temporal lump: Case report and review of literature. (27057226)	Panigrahi S.... Das S.	2016
34	Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells. (26892009)	Tanaka T.... Iino M.	2016
35	Giant intrapelvic malignant peripheral nerve sheath tumor mimicking disc herniation: A case report. (27900106)	Wang P.... Mu W.	2016
36	Malignant Peripheral Nerve Sheath Tumor With Osseous Heterologous Differentiation in Uncommon Locations (Heart and Retropharynx). (26888958)	Machado I.... Llombart-Bosch A.	2016
37	Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. (26642794)	Nobeyama Y.... Nakagawa H.	2016
38	Breast metastases from a malignant peripheral nerve sheath tumor of the kidney: An unusual presentation. (27453670)	Koppisetty S.... Rajpurkar A.	2016
39	Fine-needle aspiration cytology of epithelioid malignant peripheral nerve sheath tumor: A case report and review of the literature. (26646298)	Jiwani S.... Jeffus S.	2016
40	Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. (26650448)	Kivlin C.M.... Torres K.E.	2016
41	Low-grade malignant peripheral nerve sheath tumor: a report of the first case in the breast and literature review. (26899712)	Redzepagic J.... Vranic S.	2016
42	MAGEA3 methylation status is associated with prognosis of malignant peripheral nerve sheath tumor and with neurofibroma type in neurofibromatosis type 1. (27422441)	Nobeyama Y.... Nakagawa H.	2016
43	Superficial malignant peripheral nerve sheath tumor with overlying intradermal melanocytic nevus mimicking spindle cell melanoma. (27687011)	Jackson C.R.... Billings S.D.	2016
44	Malignant Peripheral Nerve Sheath Tumor -A Rare Malignancy in Mandible. (27504425)	Majumdar S.... Kumar S.P.	2016
45	Massive exophytic malignant peripheral nerve sheath tumor. (27257459)	Khorsand D.... Davidson D.	2016
46	Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1. (28052660)	Hwang I.K.... Han J.W.	2016
47	A Rare Malignant Peripheral Nerve Sheath Tumor of the Maxilla Mimicking a Periapical Lesion. (27994888)	Arruda J.A.... Sobral A.P.	2016
48	Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor. (26993773)	Zhou W.... Yang J.	2016
49	Tracheal obstruction caused by cervical malignant peripheral nerve sheath tumor. (26116738)	Kitamura S.... Nakajima N.	2015
50	Malignant peripheral nerve sheath tumor of the forehead. (25502700)	Irkoren S.... Tataroglu C.	2015

Genes related to Malignant Peripheral Nerve Sheath Tumor

Sources:
⁸Cosmic, ¹³DISEASES, ²¹GeneCards, ⁵⁰Novoseek, ⁵⁴Orphanet
See all MalaCards sources

Genes related to Malignant Peripheral Nerve Sheath Tumor (2 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication	PubmedIds
1	HTRA1	HtrA Serine Peptidase 1	350.00	Gene fusion ⁵⁴
2	SH3PXD2A	SH3 And PX Domains 2A	350.00	Gene fusion ⁵⁴
3	NF1	Neurofibromin 1	58.63	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	10534774, 17348023, 19414372 more 9354454, 16908010, 12296648, 20124472, 12152785, 10469433, 15602756, 19414372, 12152785, 11406645, 10812008, 12432832, 10362810, 16761762, 12810251, 15602756, 10469433, 20124472, 17551851, 13679444, 19634141, 12612091
4	VIM	Vimentin	53.35	Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	17725305, 11580072, 16481232 more 11732802, 11732802, 18154670
5	NF2	Neurofibromin 2	50.82	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	10403310, 20399579, 12152785 more 12810251, 9354454
6	S100B	S100 Calcium Binding Protein B	48.84	Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	11145248, 11732802, 17119986 more 18480004, 18636017, 20025639, 15774214, 14508395, 11580072, 10584703, 17910355, 7645984, 10891546, 11438454, 18547346, 11732802
7	SOX10	SRY-Box 10	48.34	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	16036108, 16510576, 18636017
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	47.20	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	14508395, 12152785, 10469453 more 11406645, 10595918, 10595915, 14519636, 16540739, 15715079, 14722917, 15207265, 10595915, 16540739, 11406645, 10469453, 12812137, 12152785
9	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	46.84	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	16357008, 16357008, 14673600 more 18281533, 17558420
10	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	44.50	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	16357008, 16481232, 16235251 more 16357008, 11865845
11	NRG1	Neuregulin 1	44.31	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	15897877, 12838503, 19306381 more 15015657, 12838503
12	TOP2A	Topoisomerase (DNA) II Alpha	41.92	Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	14673046, 14673046, 16721726 more 14508395, 18522746
13	EGFR	Epidermal Growth Factor Receptor	39.32	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	10791998, 18650488, 19330289 more 19921253, 18448562, 12152785, 17235305, 19948538
14	MUC1	Mucin 1, Cell Surface Associated	37.91	Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	10549251, 10891546
15	S100A1	S100 Calcium Binding Protein A1	35.94	Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	18547346, 1803052, 11536443 more 16481232, 19154261
16	CDK4	Cyclin Dependent Kinase 4	35.53	DISEASES inferred ¹³ Novoseek inferred ⁵⁰ GeneCards inferred via : Disorders, Publications (show sections)	10469453
17	SMARCB1	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1	34.53	DISEASES inferred ¹³ GeneCards inferred via : Disorders, Publications (show sections)
18	CHGA	Chromogranin A	28.84	GeneCards inferred via : Disorders, Publications (show sections)
19	ACTC1	Actin, Alpha, Cardiac Muscle 1	24.82	Novoseek inferred ⁵⁰ GeneCards inferred via : Publications (show sections)	16481232
20	TP53	Tumor Protein P53	23.88	DISEASES inferred ¹³ GeneCards inferred via : Publications (show sections)

Variations for Malignant Peripheral Nerve Sheath Tumor

Sources:
⁶CNVD
See all MalaCards sources

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

⁶ (show all 45)

id	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	17387	1	142600000	147000000	Gain		Malignant peripheral nerve sheath tumor
2	22132	1	165500000	170900000	Gain		Malignant peripheral nerve sheath tumor
3	23047	1	170900000	176000000	Gain		Malignant peripheral nerve sheath tumor
4	49109	11	102900000	112500000	Loss		Malignant peripheral nerve sheath tumor
5	49995	11	112500000	121200000	Loss		Malignant peripheral nerve sheath tumor
6	53584	11	31000000	36400000	Loss		Malignant peripheral nerve sheath tumor
7	61507	12	1	3100000	Gain	FOXM1	Malignant peripheral nerve sheath tumor
8	65742	12	21200000	26300000	Amplification	SOX5	Malignant peripheral nerve sheath tumor
9	66816	12	3300000	10100000	Gain		Malignant peripheral nerve sheath tumor
10	67235	12	38200000	49100000	Gain		Malignant peripheral nerve sheath tumor
11	69080	12	5300000	10000000	Gain	NOL1	Malignant peripheral nerve sheath tumor
12	69882	12	56428269	56432431	Gain	CDK4	Malignant peripheral nerve sheath tumor
13	69960	12	56600000	71500000	Gain		Malignant peripheral nerve sheath tumor
14	71535	12	71500000	86700000	Gain		Malignant peripheral nerve sheath tumor
15	73254	12	92600000	109000000	Gain		Malignant peripheral nerve sheath tumor
16	73259	12	92600000	96200000	Gain		Malignant peripheral nerve sheath tumor
17	75380	13	19500000	25500000	Gain		Malignant peripheral nerve sheath tumor
18	76637	13	34000000	55300000	Gain		Malignant peripheral nerve sheath tumor
19	79536	13	73300000	77200000	Gain		Malignant peripheral nerve sheath tumor
20	85488	14	47200000	67900000	Loss		Malignant peripheral nerve sheath tumor
21	87451	14	73800000	107349540	Gain		Malignant peripheral nerve sheath tumor
22	97234	16	1	10500000	Gain		Malignant peripheral nerve sheath tumor
23	102841	16	57400000	90354753	Gain		Malignant peripheral nerve sheath tumor
24	105377	16	7900000	14800000	Gain		Malignant peripheral nerve sheath tumor
25	115613	17	58300000	81195210	Gain		Malignant peripheral nerve sheath tumor
26	124065	19	1	13900000	Gain		Malignant peripheral nerve sheath tumor
27	147242	2	61300000	68600000	Gain		Malignant peripheral nerve sheath tumor
28	150135	2	96800000	114400000	Gain		Malignant peripheral nerve sheath tumor
29	163892	22	32200000	44200000	Gain		Malignant peripheral nerve sheath tumor
30	172609	3	184500000	198022430	Gain		Malignant peripheral nerve sheath tumor
31	174546	3	2800000	16400000	Gain		Malignant peripheral nerve sheath tumor
32	175421	3	39400000	54400000	Gain		Malignant peripheral nerve sheath tumor
33	196162	5	159900000	180915260	Gain		Malignant peripheral nerve sheath tumor
34	198008	5	18400000	23300000	Gain		Malignant peripheral nerve sheath tumor
35	209673	6	27000000	57000000	Gain		Malignant peripheral nerve sheath tumor
36	213890	6	52900000	70000000	Gain		Malignant peripheral nerve sheath tumor
37	220382	7	13800000	43300000	Gain		Malignant peripheral nerve sheath tumor
38	227906	7	72200000	86400000	Gain		Malignant peripheral nerve sheath tumor
39	240607	8	52600000	146364022	Gain		Malignant peripheral nerve sheath tumor
40	241476	8	6200000	36500000	Gain		Malignant peripheral nerve sheath tumor
41	244863	9	1	14200000	Gain		Malignant peripheral nerve sheath tumor
42	247559	9	130300000	135900000	Gain		Malignant peripheral nerve sheath tumor
43	249423	9	14200000	28000000	Loss		Malignant peripheral nerve sheath tumor
44	255080	9	72339785	73251640	Dramatically overexp ressed,genomicallyamplified	TRPM3	Malignant peripheral nerve sheath tumor
45	255774	9	84100000	102600000	Gain		Malignant peripheral nerve sheath tumor

Expression for genes affiliated with Malignant Peripheral Nerve Sheath Tumor

Sources:
¹⁸Gene Expression Omnibus DataSets
See all MalaCards sources

Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.

Pathways for genes affiliated with Malignant Peripheral Nerve Sheath Tumor

Sources:
³Cell Signaling Technology, ³⁴KEGG, ⁴²NCBI BioSystems Database, ⁵⁵PathCards, ⁵⁶PharmGKB, ⁵⁸QIAGEN, ⁵⁹R&D Systems, ⁶⁰Reactome
See all MalaCards sources

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 25)

id	Super pathways	Score	Top Affiliating Genes
1	Gefitinib Pathway, Pharmacokinetics⁵⁶ Show member pathways Pazopanib Pathway, Pharmacokinetics⁵⁶ Erlotinib Pathway, Pharmacokinetics⁵⁶ Warfarin Pathway, Pharmacokinetics⁵⁶ Imatinib Pathway, Pharmacokinetics/Pharmacodynamics⁵⁶ Nevirapine Pathway, Pharmacokinetics⁵⁶ Doxepin Pathway, Pharmacokinetics⁵⁶ Fluoxetine Pathway, Pharmacokinetics⁵⁶	9.6	EGFR, KIT, PDGFRA
2	ATF-2 transcription factor network⁴²	9.6	CDK4, NF1, PDGFRA
3	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers⁵⁹	9.5	PDGFRA, S100B, SOX10, VIM
4	Platinum drug resistance³⁴	9.4	CDKN2A, TOP2A, TP53
5	Gastric Cancer Network 2⁴²	9.3	EGFR, TOP2A, TP53
6	Tyrosine Kinases / Adaptors³	9.3	EGFR, KIT, NRG1, PDGFRA
7	Oncogene Induced Senescence⁶⁰	9.2	CDK4, CDKN2A, TP53
8	Signaling by PTK6⁶⁰ Show member pathways PTK6 Expression⁶⁰ PTK6 promotes HIF1A stabilization⁶⁰ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases⁶⁰ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1⁶⁰ RAS signaling downstream of NF1 loss-of-function variants⁶⁰ PTK6 Regulates Proteins Involved in RNA Processing⁶⁰ PTK6 Activates STAT3⁶⁰ PTK6 Down-Regulation⁶⁰	9.2	CDK4, EGFR, NF1, NRG1
9	Photodynamic therapy-induced AP-1 survival signaling.⁴²	9.1	CDKN2A, EGFR, PDGFRA, TP53
10	Central carbon metabolism in cancer³⁴	9.1	EGFR, KIT, PDGFRA, TP53
11	Integrated Breast Cancer Pathway⁴²	9.0	CDK4, EGFR, NF1, TP53
12	Spinal Cord Injury⁴²	8.9	CDK4, EGFR, TP53, VIM
13	Pancreatic cancer³⁴ Show member pathways Chronic myeloid leukemia³⁴ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer⁴²	8.9	CDK4, CDKN2A, EGFR, TP53
14	Bladder cancer⁴² ³⁴ Show member pathways Bladder Cancer⁴²	8.9	CDK4, CDKN2A, EGFR, TP53
15	MAPK Signaling: Mitogen Stimulation Pathway⁵⁹ Show member pathways Akt Signaling Pathway⁵⁹	8.9	CDK4, EGFR, PDGFRA, TP53
16	MicroRNAs in cancer³⁴	8.9	CDKN2A, EGFR, PDGFRA, TP53, VIM
17	Cardiac Progenitor Differentiation⁴²	8.8	ACTC1, KIT, NRG1, PDGFRA
18	Downstream signaling events of B Cell Receptor (BCR)⁶⁰ Show member pathways Signaling by the B Cell Receptor (BCR)⁶⁰ Activation of RAS in B cells⁶⁰	8.8	EGFR, KIT, NRG1, PDGFRA, TP53
19	DNA Damage³	8.7	CDK4, CDKN2A, TOP2A, TP53, VIM
20	PI3K-Akt signaling pathway³⁴	8.6	CDK4, EGFR, KIT, PDGFRA, TP53
21	Pathways in cancer³⁴	8.3	CDK4, CDKN2A, EGFR, KIT, PDGFRA, TP53
22	Glioblastoma Multiforme⁵⁸	8.2	CDK4, CDKN2A, EGFR, NF1, NF2, PDGFRA
23	Cytokine Signaling in Immune system⁶⁰ Show member pathways Signaling by Interleukins⁶⁰	8.0	EGFR, KIT, MUC1, NF1, NRG1, PDGFRA
24	Glioma³⁴ Show member pathways Endocrine resistance³⁴ Signaling Pathways in Glioblastoma⁴² Prostate cancer³⁴ Breast cancer³⁴ Non-small cell lung cancer³⁴ Melanoma³⁴ EGFR tyrosine kinase inhibitor resistance³⁴ Vemurafenib Pathway, Pharmacodynamics⁵⁶	7.8	CDK4, CDKN2A, EGFR, KIT, NF1, NRG1
25	ERK Signaling⁵⁸ Show member pathways ILK Signaling⁵⁸ Molecular Mechanisms of Cancer⁵⁸ MAPK Signaling⁵⁸ Rho Family GTPases⁵⁸	7.0	CDK4, CDKN2A, EGFR, KIT, MUC1, NF1

GO Terms for genes affiliated with Malignant Peripheral Nerve Sheath Tumor

Sources:
¹⁹Gene Ontology
See all MalaCards sources

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	cell body	GO:0044297	9.9	ACTC1, NF2, NRG1
2	nucleolus	GO:0005730	8.6	CDK4, CDKN2A, NF1, NF2, SMARCB1, TOP2A
3	protein complex	GO:0043234	8.0	CDK4, PDGFRA, S100A1, SMARCB1, TOP2A, TP53
4	cytoplasm	GO:0005737	5.3	ACTC1, CDK4, CDKN2A, EGFR, HTRA1, KIT

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 24)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of phospholipase C activity	GO:0010863	10.7	KIT, PDGFRA
2	negative regulation of cell-matrix adhesion	GO:0001953	10.6	CDKN2A, NF1, NF2
3	peripheral nervous system development	GO:0007422	10.5	NF1, NRG1, SOX10
4	somatic stem cell division	GO:0048103	10.5	CDKN2A, KIT
5	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	10.3	KIT, NRG1, PDGFRA
6	mast cell chemotaxis	GO:0002551	10.3	CHGA, KIT
7	mast cell cytokine production	GO:0032762	10.3	CHGA, KIT
8	positive regulation of histone H4 acetylation	GO:0090240	10.3	MUC1, SMARCB1
9	replicative senescence	GO:0090399	10.2	CDKN2A, TP53
10	cardiac myofibril assembly	GO:0055003	10.2	ACTC1, PDGFRA
11	positive regulation of fibroblast proliferation	GO:0048146	10.1	CDK4, EGFR, PDGFRA
12	Ras protein signal transduction	GO:0007265	10.1	CDKN2A, NF1, TP53
13	peptidyl-tyrosine phosphorylation	GO:0018108	10.0	EGFR, KIT, NRG1, PDGFRA
14	phosphatidylinositol phosphorylation	GO:0046854	10.0	EGFR, KIT, NRG1, PDGFRA
15	MAPK cascade	GO:0000165	9.9	EGFR, KIT, NF1, NRG1, PDGFRA
16	regulation of phosphatidylinositol 3-kinase signaling	GO:0014066	9.8	EGFR, KIT, NRG1, PDGFRA
17	regulation of cell proliferation	GO:0042127	9.6	CDK4, EGFR, KIT, NF1, NF2
18	negative regulation of cell proliferation	GO:0008285	9.5	CDKN2A, NF1, NF2, SMARCB1, TP53
19	phosphatidylinositol-mediated signaling	GO:0048015	9.5	EGFR, KIT, NRG1, PDGFRA, TP53
20	wound healing	GO:0042060	9.4	EGFR, NF1, NRG1, PDGFRA
21	positive regulation of cell proliferation	GO:0008284	9.3	CDK4, EGFR, KIT, NRG1, PDGFRA, S100B
22	positive regulation of apoptotic process	GO:0043065	9.2	CDK4, CDKN2A, NF1, S100B, TOP2A, TP53
23	positive regulation of gene expression	GO:0010628	9.1	ACTC1, KIT, NRG1, TP53, VIM
24	positive regulation of transcription from RNA polymerase II promoter	GO:0045944	8.6	CDKN2A, EGFR, NRG1, SMARCB1, SOX10, TOP2A

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 7)

id	Name	GO ID	Score	Top Affiliating Genes
1	signal transducer, downstream of receptor, with protein tyrosine kinase activity	GO:0004716	10.3	EGFR, KIT
2	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.9	EGFR, KIT, NRG1, PDGFRA
3	protein tyrosine kinase activity	GO:0004713	9.9	EGFR, KIT, NRG1, PDGFRA
4	Ras guanyl-nucleotide exchange factor activity	GO:0005088	9.8	EGFR, KIT, NRG1, PDGFRA
5	p53 binding	GO:0002039	9.7	MUC1, SMARCB1, TP53
6	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.6	EGFR, KIT, PDGFRA
7	identical protein binding	GO:0042802	9.2	EGFR, S100A1, S100B, SOX10, TP53, VIM